ORLANDO — ICU patients with a central venous access device had a smaller incidence rate of device-related complications with 4% tetrasodium ethylenediaminetetraacetic acid vs. control locking fluid, according to results presented here.
In addition to being presented at the American Thoracic Society International Conference, these data were simultaneously published in JAMA.
“The use of 4% [ethylenediaminetetraacetic acid (EDTA)]-locking fluid reduced the incidence of a composite endpoint of CVAD complications compared with [a] saline or 4% citrate control group,” Steven Reynolds, MD, ICU